GSK announces positive results from phase III trial of Nucala ...
Sep 6, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD).
GSK says Nucala hits the target in new COPD trial
3 days ago · GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.
US FDA accepts GSK’s submission for the use of Nucala …
Dec 9, 2024 · GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the regulatory review process to obtain a new indication for the use of Nucala (mepolizumab), as an add-on maintenance treatment for patients with chronic obstructive pulmonary disease (COPD) with an ...
GSK’s asthma blockbuster Nucala secures win in COPD Phase III trial
Sep 6, 2024 · GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive pulmonary disease (COPD). Data from the MATINEE study showed...
GSK Builds Nucala’s COPD Case With Phase III Win
Sep 6, 2024 · GSK on Friday announced topline results from the Phase III MATINEE trial, which found that its injectable antibody Nucala (mepolizumab) lessened exacerbations in patients with chronic obstructive pulmonary disease.
GSK antibody drug reduces COPD attacks in trial | BioPharma Dive
Sep 6, 2024 · GSK initiated the new study after failing to win approval for Nucala in COPD in 2018. At the time, the Food and Drug Administration asked for more clinical data to support the expanded indication. Nucala is a biologic therapy that targets a key messenger protein in the body called interleukin-5.
GSK's Nucala gains US use in rare autoimmune disease
Jan 12, 2025 · GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA).
GSK : Phase III Trial Of Nucala In Chronic Obstructive ... - Nasdaq
Sep 6, 2024 · (RTTNews) - GSK plc (GSK, GSK.L) announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5...
GSK Nucala succeeds in Phase 3 COPD trial (NYSE:GSK)
Sep 6, 2024 · GSK (NYSE: GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for patients with chronic obstructive pulmonary disease (COPD), a common...
FDA to review GSK’s Nucala for COPD - Yahoo Finance
Dec 10, 2024 · The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for chronic obstructive...